[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yantai Yuhuangding Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":93},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100655610","phase-2-a-phase-ii-study-of-tislelizumab-plus-anlotinib-consolidation-after-chemoradiotherapy-in-ls-sclc-100655610",false,"NCT07815223","A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC","A Prospective, Single-Arm, Phase II Study of Tislelizumab Plus Anlotinib as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Without Progression After Concurrent or Sequential Chemoradiotherapy","Inclusion Criteria:\n\n1. Provide written informed consent and be willing and able to comply with study requirements and scheduled assessments;\n2. Be aged 18-75 years at the time of consent;\n3. Have an ECOG performance status of 0 or 1;\n4. Have histologically or cytologically confirmed small-cell lung cancer;\n5. Have radiologically confirmed limited-stage disease;\n6. Have achieved a complete response, partial response, or stable disease after concurrent or sequential chemoradiotherapy, according to RECIST version 1.1;\n7. Have a life expectancy of at least 3 months;\n8. Have adequate organ function.\n\nExclusion Criteria:\n\n1. Received systemic immunostimulatory agents, including interferons, interleukin 2, or tumour necrosis factor, within 4 weeks or five half-lives before the first dose of study treatment, whichever is longer; previous cancer vaccines are permitted;\n2. Received any traditional Chinese herbal medicine for cancer control within 14 days before the first dose;\n3. Required systemic corticosteroids equivalent to more than 10 mg per day of prednisone or other immunosuppressive treatment within 14 days before the first dose;\n4. Received a live vaccine within 4 weeks before the first dose; inactivated seasonal influenza vaccines are permitted, but live intranasal influenza vaccines are not;\n5. Underwent major surgery requiring general anaesthesia within 28 days before the first dose;\n6. Had previous allogeneic stem-cell or organ transplantation;\n7. Have clinically significant pericardial effusion;\n8. Have uncontrolled pleural effusion or ascites requiring drainage within 2 weeks before enrolment;\n9. Have active autoimmune disease or a history of autoimmune disease with a risk of recurrence;\n10. Have a history of interstitial lung disease or non-infectious pneumonitis, or uncontrolled systemic disease, including diabetes, hypertension, pulmonary fibrosis, or acute lung disease;\n11. Have a severe chronic or active infection requiring systemic antibacterial, antifungal, or antiviral treatment within 2 weeks before the first dose, including tuberculosis;\n12. Have had another active malignancy within 2 years before the first dose, except the cancer under investigation or definitively treated localised cancers, including resected basal-cell or squamous-cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast;\n13. Have untreated chronic hepatitis B, chronic HBV infection with an HBV DNA concentration of at least 500 IU\u002FmL (2500 copies\u002FmL), or active hepatitis C;\n14. Have a known history of HIV infection;\n15. Have clinically significant cardiovascular risk factors;\n16. Have unresolved toxicities from previous anticancer treatment that have not returned to baseline or stabilised, except adverse events unlikely to pose a safety risk, such as alopecia, neuropathy, or specified laboratory abnormalities;\n17. Have a history of severe hypersensitivity to monoclonal antibodies.","ALL","18 Years","75 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This prospective, single-arm, phase II study aims to evaluate the efficacy and safety of tislelizumab plus anlotinib as consolidation therapy in patients with limited-stage small cell lung cancer (LS-SCLC) who have not progressed following concurrent or sequential chemoradiotherapy.",[27],"SCLC, Limited Stage",[29],"consolidation therapy","RECRUITING","2026-09-07",{"date":33,"type":34},"2026-09-11","ACTUAL",{"date":36,"type":34},"2025-11-04",{"date":38,"type":21},"2029-12-31",{"name":40,"class":41},"Yantai Yuhuangding Hospital","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":56,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":42},"100597111","phase-2-a-prospective-single-center-phase-ii-study-of-sacituzumab-tirumotecan-in-combination-with-pembrolizumab-for-neoadjuvant-treatment-of-triple-negative-breast-cancer-tnbc-100597111","NCT07054242","A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC)","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed stage II-III (T1cN1-2 or T2-4N0-2) triple-negative breast cancer (TNBC), defined as:\n\n   * Immunohistochemistry (IHC) showing ER and PR \\\u003C1%\n   * HER2-negative per 2028 ASCO-CAP guidelines (IHC 0\u002F1+ or IHC 2+\u002FISH-)\n2. Available tumor tissue sample for biomarker analysis.\n3. At least one measurable lesion as per RECIST 1.1 criteria.\n4. ECOG performance status 0-1.\n5. Adequate organ function as evidenced by:\n\n   * Absolute neutrophil count ≥1.5×10⁹\u002FL (no G-CSF support within 14 days)\n   * Platelets ≥100×10⁹\u002FL (no transfusion within 14 days)\n   * Hemoglobin \\>9 g\u002FdL (no transfusion\u002FESA within 14 days)\n   * Total bilirubin ≤1.5×ULN\n   * AST\u002FALT ≤1.5×ULN\n   * Alkaline phosphatase ≤2.5×ULN\n   * Serum creatinine ≤1.5×ULN or CrCl ≥60 mL\u002Fmin (Cockcroft-Gault)\n   * INR\u002FPT ≤1.5×ULN\n   * TSH within normal range (or normal FT3\u002FFT4 if TSH abnormal)\n   * Normal cardiac enzymes (isolated abnormalities allowed if clinically insignificant)\n6. No prior anti-cancer therapy for current diagnosis.\n7. For women of childbearing potential and men with WOCBP partners: agreement to use effective contraception from screening until 6 months post-treatment.\n8. Willing and able to comply with study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n1. LVEF \\\u003C50% by ECHO\u002FMUGA or significant cardiac disease (NYHA Class III\u002FIV).\n2. Prior chemotherapy, targeted therapy, or radiotherapy for current breast cancer.\n3. Previous treatment with immune checkpoint inhibitors (anti-PD-1\u002FL1, anti-CTLA-4) or T-cell targeting therapies.\n4. Prior Trop-2 directed therapy or topoisomerase I inhibitor treatment.\n5. Other malignancies within 5 years (except adequately treated CIS of cervix, BCC, or cutaneous SCC).\n6. Severe ocular surface disease (dry eye syndrome, meibomian gland dysfunction, or corneal disorders impairing healing).\n7. Known hypersensitivity to study drug components.\n8. History of immunodeficiency disorders or organ transplantation.\n9. Current or history of:\n\n   * Steroid-requiring interstitial lung disease\u002Fpneumoniti Unresolved ILD\u002Fpneumonitis on screening imaging\n\n   Clinically significant pulmonary conditions including:\n   * Recent pulmonary embolism (≤3 months)\n   * Severe asthma\u002FCOPD\u002Frestrictive lung disease\n   * Pleural effusion requiring intervention\n   * Connective tissue disease with pulmonary involvement\n   * Prior pneumonectomy\n10. Active autoimmune disease requiring systemic treatment (past 2 years), except:\n\n    * Hormone replacement therapy\n    * Physiologic corticosteroid replacement\n11. Active infection requiring systemic therapy within 14 days prior to initiation.\n12. Uncontrolled comorbidities that may:\n\n    * Compromise patient safety\n    * Interfere with study completion\n13. Any condition that in the investigator's judgment may:\n\n    * Affect study drug evaluation\n    * Compromise safety assessments\n    * Interfere with data interpretation\n    * Otherwise contraindicate participation",{"count":50,"type":21},52,[24],"This is a prospective, single center, phase II study to enroll participants with stage II or III TNBC who have not previously undergone systemic therapy. The primary endpoint is pCR in the ITT population. The study aims to enroll 52 participants. Eligible participants will receive a combination therapy of SKB264 and Pembrolizumab.\n\nExperimental arm: SKB264 will be administered intravenously (IV) at a dose of 4 mg\u002Fkg every two weeks (Q2W); Pembrolizumab will be administered intravenously at a dose of 200mg every three weeks (Q3W) All enrolled participants will initially receive SKB264 plus Pembrolizumab for 8 weeks. Based on early imaging and biopsy assessment, patients who deemed as responders continue to receive combined drug therapy for 10 weeks, followed by surgical treatment. Patients who assessed as non-responders will be treated at the discretion of the physician.\n\nParticipants will undergo regular tumor assessments based on RECIST 1.1 criteria. Imaging assessments will be conducted every 9 weeks (±1 week) for the first 18 weeks following treatment initiation, and every 12 weeks (±1 week) thereafter, until confirmed disease progression, initiation of a new antitumor treatment, withdrawal of consent, loss to follow-up, death, or study end, whichever occurs first. After termination of the study treatment, participants must complete the EOT visit and a safety follow-up, and undergo survival visits every 3 months (±14 days) post the last dose to collect information on survival, new antitumor treatments received.",[54,55],"Neoadjuvant Therapy","Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer",[57,58,59,60],"SKB264","Pembrolizumab","TNBC","Neoadjuvant therapy","NOT_YET_RECRUITING","2025-09-26",{"date":64,"type":34},"2025-10-01",{"date":66,"type":21},"2025-10-30",{"date":68,"type":21},"2028-06-30",{"name":40,"class":41},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":16,"minAge":17,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":22,"phases":81,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":4},"100554494","cpvi-alone-versus-cpvi-plus-low-voltage-areas-ablation-during-sr-versus-cpvi-plus-low-voltage-areas-ablation-during-af-for-the-treatment-of-caf-100554494","NCT06499818","CPVI Alone Versus CPVI Plus Low-Voltage Areas Ablation During SR Versus CPVI Plus Low-Voltage Areas Ablation During AF for the Treatment of CAF","Circumferential Pulmonary Vein Isolation Alone Versus CPVI Plus Low-Voltage Areas Ablation During SR Versus CPVI Plus Low-Voltage Areas Ablation During AF for the Treatment of CAF","Inclusion Criteria:\n\n1. Patients age is 18-80 years;\n2. Patients with non-paroxysmal AF; non-paroxysmal AF will be defined as a sustained episode lasting \\> 7 days;\n3. Patients can sign the written informed consent for the study;\n4. Patients can endure the required follow-up.\n\nExclusion Criteria:\n\n1. Patients who had previously undergone atrial fibrillation, atrial tachycardia, or atypical atrial flutter ablation\n2. Preoperative combined atrial tachycardia (≥30S) and atypical atrial flutter\n3. Left atrial diameter \\>55mm\n4. Left ventricular ejection fraction \\\u003C35%\n5. Left atrial thrombus\n6. Postoperative cardiac surgery\n7. After valve replacement\n8. After permanent pacemaker implantation\n9. hypertrophic cardiomyopathy\n10. Patients with moderate-to-severe aortic valve disease, moderate-to-severe mitral stenosis, and severe other valvular disease\n11. Hemorrhagic stroke within 6 months\n12. Transient ischemic attack or ischemic stroke within 1 month\n13. Mental disorder or history of mental illness and inability to cooperate voluntarily\n14. Breastfeeding, pregnancy and women planning or likely to become pregnant\n15. Life expectancy \\\u003C12 months\n16. Participating in other interventional clinical trials\n17. The researchers judged that it was not suitable for inclusion in this study",true,"80 Years",{"count":80,"type":21},150,[82],"NA","The primary objective of this investigation is to compare the efficacy of Three different AF ablation strategies in patients with Persistent atrial fibrillation: CPVI plus Low-Voltage Areas ablation during sinus rhythm Versus. CPVI Plus Low-Voltage Areas Ablation During AF and CPVI alone.",[85],"Atrial Fibrillation","2024-07-11",{"date":88,"type":34},"2024-07-15",{"date":88,"type":21},{"date":91,"type":21},"2026-12-15",{"name":40,"class":41},""]